Microbot Medical Partners With Lovell Government Services to Expand Access to LIBERTY® Endovascular Robotic System Across Federal Healthcare Networks
Microbot Medical, a company focused on the development and commercialization of advanced robotic technologies for endovascular procedures, has announced a strategic agreement with Lovell Government Services aimed at expanding access to its groundbreaking LIBERTY® Endovascular Robotic System throughout major U.S. federal healthcare networks. The partnership is expected to make the innovative technology more readily available to patient populations served by the Veterans Health Administration (VHA), the Military Health System (MHS), and the Indian Health Service (IHS), improving access to advanced vascular care for veterans, active-duty military personnel, and Native American communities.
Under the agreement, Lovell Government Services will serve as Microbot Medical’s Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor. Through its established federal contracting infrastructure, Lovell will facilitate the availability of the LIBERTY® Endovascular Robotic System to healthcare facilities operating under various federal agencies. The collaboration represents a significant milestone for Microbot Medical as it seeks to broaden the commercial reach of its robotic platform while addressing the healthcare needs of underserved populations across the United States.
Expanding Access Through Federal Healthcare Systems
Federal healthcare systems play a vital role in delivering care to millions of Americans, particularly veterans, active-duty military personnel, and Indigenous communities. These organizations require access to innovative medical technologies that can improve patient outcomes and increase procedural efficiency. Through the new partnership, Microbot Medical aims to position its LIBERTY® platform within some of the nation’s most extensive healthcare networks.
The Veterans Health Administration, a division of the U.S. Department of Veterans Affairs, operates one of the largest integrated healthcare systems in the world. It provides medical services to millions of veterans through a network of hospitals, medical centers, and outpatient facilities. Similarly, the Military Health System, overseen by the Department of Defense, delivers healthcare services to active-duty service members, military retirees, and their families. The Indian Health Service, another key beneficiary of the agreement, serves Native American and Alaska Native populations through a broad range of healthcare facilities across the country.
By leveraging Lovell Government Services’ expertise in federal contracting, Microbot Medical expects to simplify procurement processes and accelerate the adoption of robotic-assisted vascular technologies across these healthcare organizations.
Lovell Government Services Brings Extensive Federal Market Experience
Lovell Government Services has built a strong reputation in government healthcare contracting since becoming a Service-Disabled Veteran-Owned Small Business vendor in 2013. The company specializes in helping medical device manufacturers and suppliers gain access to government healthcare markets while ensuring that federal agencies can meet their procurement goals related to SDVOSB participation.
Over the years, Lovell has established itself as a trusted partner within the government healthcare sector. The company has earned recognition as a four-time Inc. 5000 honoree, reflecting its sustained growth and success. Through its extensive network, Lovell serves thousands of government healthcare sites nationwide, including approximately 170 medical centers and numerous outpatient clinics.
Many of these facilities perform more than 200 peripheral endovascular procedures annually, highlighting the substantial market opportunity for Microbot Medical’s robotic technology. By integrating the LIBERTY® system into these care environments, the partnership has the potential to impact a significant number of patients requiring minimally invasive vascular procedures.
LIBERTY® System to Become Available Through Key Procurement Channels
A central element of the collaboration involves adding the LIBERTY® Endovascular Robotic System to Lovell Government Services’ Federal Supply Schedule (FSS) contract. Activation of the listing is anticipated during the third quarter of 2026.
Once activated, the system will be available through several major federal procurement platforms that healthcare facilities routinely utilize. These include:
- General Services Administration (GSA) Advantage;
- Defense Logistics Agency’s Electronic Catalog (ECAT);
- Department of Defense Distribution and Pricing Agreement (DAPA).
Availability across these procurement channels is expected to simplify purchasing decisions for federal healthcare institutions by providing streamlined access to the technology. This arrangement may also help agencies satisfy their procurement objectives related to working with Service-Disabled Veteran-Owned Small Businesses.
By reducing administrative complexity and creating established purchasing pathways, Microbot Medical hopes to accelerate the adoption of the LIBERTY® platform among federal providers.
Transforming Endovascular Care Through Robotics
The LIBERTY® Endovascular Robotic System represents one of Microbot Medical’s most significant innovations. Designed to support minimally invasive vascular procedures, the robotic platform aims to improve precision while enabling physicians to perform interventions more efficiently.
Endovascular procedures are commonly used to diagnose and treat diseases affecting blood vessels. These interventions often require high levels of accuracy and can expose physicians to prolonged radiation and physical strain. Robotic-assisted technologies have emerged as an important advancement in addressing these challenges by allowing physicians to perform procedures remotely while maintaining control and precision.
Microbot Medical’s LIBERTY® system has been developed to provide greater flexibility and procedural efficiency. The platform is designed to support peripheral vascular interventions while potentially reducing operator fatigue and improving overall workflow. As healthcare systems increasingly embrace robotics and automation, the LIBERTY® system positions itself as a next-generation solution within the field of endovascular medicine.
Commitment to Veterans and Military Communities
Chris Lovell, Chief Executive Officer of Lovell Government Services and a retired Major in the United States Marine Corps, emphasized the importance of expanding access to innovative healthcare solutions for veterans and active-duty service members.
According to Lovell, the partnership aligns with the company’s mission of connecting government healthcare providers with advanced technologies that can improve patient outcomes while making procurement more efficient. He noted that the LIBERTY® Endovascular Robotic System represents a major advancement in minimally invasive vascular care and expressed enthusiasm about supporting its availability across federal healthcare networks.
Lovell also highlighted the broader significance of the collaboration for Native American communities served through the Indian Health Service, emphasizing the need to ensure equitable access to cutting-edge healthcare technologies across diverse patient populations.
Strengthening Commercial Momentum
Microbot Medical views the agreement as an important component of its broader commercialization strategy. The company has been focused on increasing awareness and adoption of the LIBERTY® system while building partnerships that create efficient purchasing pathways for healthcare providers.
Christina Bailey, Vice President of U.S. Sales at Microbot Medical, underscored the personal significance of the initiative. A former Olympian who represented the United States in two Olympic Games, Bailey expressed pride in supporting efforts that ensure veterans and military personnel have access to advanced medical technologies.
She indicated that the partnership with Lovell Government Services builds upon the company’s ongoing commercial momentum and provides a foundation for increasing awareness of the LIBERTY® platform across Lovell’s extensive network of healthcare facilities.
Bailey emphasized that contracted access is an essential part of the company’s strategy. By establishing reliable procurement channels and ensuring product availability, Microbot Medical hopes to instill confidence among healthcare providers and facilitate broader adoption of the technology.
As interest in robotic-assisted vascular procedures continues to grow, the company believes this is an opportune time to establish a relationship with Lovell and pursue long-term opportunities throughout federal healthcare systems.
Addressing Growing Demand for Advanced Vascular Technologies
The prevalence of vascular diseases and the increasing need for minimally invasive treatment options have driven demand for innovative technologies that enhance procedural outcomes. Healthcare systems are increasingly seeking solutions that can improve efficiency, support physician performance, and deliver better experiences for patients.
Robotic-assisted systems represent an evolving segment of the healthcare industry, with growing adoption across various specialties. By introducing the LIBERTY® platform to federal healthcare providers, Microbot Medical hopes to contribute to the modernization of vascular care while supporting physicians in delivering high-quality treatment.
The ability to access the technology through familiar procurement channels may further accelerate its integration into hospitals and outpatient centers serving military and veteran populations.
The partnership between Microbot Medical and Lovell Government Services marks an important step toward expanding access to advanced robotic-assisted vascular care within the United States. Through established government contracting systems and broad healthcare networks, the companies aim to ensure that veterans, active-duty military personnel, and Native American communities benefit from cutting-edge medical technologies.
With activation of the Federal Supply Schedule expected in the third quarter of 2026 and additional availability through GSA Advantage, ECAT, and DAPA platforms, Microbot Medical is positioning the LIBERTY® Endovascular Robotic System for wider adoption throughout federal healthcare facilities.
As robotic technologies continue to reshape modern medicine, the collaboration underscores a shared commitment to improving patient outcomes, simplifying procurement, and delivering innovative solutions to those who have served the nation and communities that rely on federal healthcare systems.
Source link: https://ir.microbotmedical.com/
